News
Chemomab Therapeutics
CMMB · NASDAQ
$1.18+$0.01 (+0.85%)TodayMarket closed ·
Prev close $1.17
Latest news
- Press releaseGlobe Newswire
Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference
- Press releaseGlobe Newswire
Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
- Press releaseGlobe Newswire
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
- Press releaseGlobe Newswire
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
- Press releaseGlobe Newswire
Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit
- Press releaseGlobe Newswire
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
- Press releaseGlobe Newswire
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis
- Press releaseGlobe Newswire
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releaseGlobe Newswire
Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- News
Market-Moving News for February 19th
- Press releaseGlobe Newswire
Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis
- News
Earnings Scheduled For November 14, 2024
- Press releaseGlobe Newswire
Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update
- Press releaseGlobe Newswire
Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.